This guide is currently available in English. A Spanish version is in progress.
Sourcing Exosomes in Maryland
Licensed Maryland practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Maryland buyers need their own professional license and NPI; the wholesale distributor permit is the supplier’s obligation, not the purchaser’s.
One Maryland provision deserves more attention than it usually gets. Health Occupations 12-6C-03(f) says a person may not purchase or obtain a prescription drug or device except from a permitted wholesale distributor, a licensed pharmacist, or an authorized prescriber, which makes confirming a supplier’s standing a statutory matter here rather than mere diligence.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Maryland? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material. Compounded preparations are not available in this state at this time |
| Last reviewed | 16 October 2026 |
Ordering from Maryland
ExaVeyra ships to licensed practices in all 50 states, Maryland included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Maryland professional license in good standing, verifiable through the Maryland Board of Physicians license lookup or the Maryland Board of Nursing verification portal.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- A Maryland sales and use tax license and resale certificate through the Comptroller of Maryland if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Maryland permits wholesale distribution of prescription drugs and prescription devices through the Board of Pharmacy. A wholesale distributor holds a permit before engaging in wholesale distribution in the state, manufacturers’ exclusive distributors and third-party logistics providers hold the same permit, and out-of-state applicants qualify through a Board-recognized accreditation program or through reciprocity with a state whose requirements are substantially equivalent. The distinctive feature is downstream: Health Occ. 12-6C-03(f) bars anyone from purchasing a prescription drug or device except from a permitted wholesale distributor, a licensed pharmacist, or an authorized prescriber, which gives a Maryland buyer a statutory reason to confirm a supplier’s standing. The permit itself sits with the distributor, not with the purchasing practice.
Md. Code Ann., Health Occ. tit. 12, subtit. 6C · Maryland Board of Pharmacy
Maryland regenerative-medicine law
Maryland has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
Maryland does have stem cells in its statute books, which causes regular confusion. Section 10-434 of the Economic Development Article creates the Maryland Stem Cell Research Fund, established in 2006 and administered by the Maryland Technology Development Corporation with its Stem Cell Research Commission. That is a grant and loan program directed at state-funded research, not an authorization to practice, and it neither permits nor conditions any clinical service. No Maryland statute addresses unapproved regenerative therapy in clinical practice, so practice in this area is governed by the Medical Practice Act, the Nurse Practice Act, and the boards that administer them, alongside federal law.
How this applies to exosomes
Maryland has not enacted a stem cell authorization law like Florida, Texas, or Georgia, a disclosure law like California, or a documentation statute like Tennessee. The Maryland Stem Cell Research Fund in section 10-434 of the Economic Development Article is sometimes cited as though it were a practice law; it funds research through grants and loans and does nothing to authorize or restrict a clinical service. There is therefore no Maryland definition to read exosomes into or out of, and exosomes are acellular extracellular vesicles that even the states with stem cell statutes have not reached, Tennessee excepted. Exosome products in Maryland are governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Maryland practice
Because certified nurse practitioners hold independent authority in Maryland, there are two workable structures rather than one, as in Colorado. An NP-led practice can evaluate and order within NP scope. A physician-led practice delegates conventionally, and a medical director is still needed where a procedure falls outside NP scope or where a payer requires one. Physicians and PAs verify through the Board of Physicians and nurses through the Board of Nursing, two separate agencies.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Maryland Board of Physicians may perform medical acts within their scope and are the source of any delegation to staff who do not hold independent authority. The board also licenses physician assistants and allied health practitioners. |
| NP / APRN | Maryland nurse practitioners hold full practice authority. HB 999 of 2015, Chapter 468, repealed the requirement that an NP attest to a collaboration and consultation agreement with a physician, effective 1 October 2015; an applicant for initial certification identifies a certified nurse practitioner or licensed physician to act as mentor for 18 months. A certified NP can therefore evaluate and order within NP scope without a physician protocol. |
| PA | Physician assistants are licensed by the Maryland Board of Physicians and practice under a written agreement with a collaborating physician on file with the board, in the scope that agreement establishes. |
| RN | Registered nurses may perform delegated treatments within their scope under the Maryland Board of Nursing’s rules, under an order from a provider with authority to issue one and after that provider has evaluated the patient. An RN does not diagnose, prescribe, or independently select a treatment. |
Good faith examination
Maryland expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Where a certified nurse practitioner holds independent authority, that provider can be the NP. Confirm current expectations with the Maryland Board of Physicians and the Maryland Board of Nursing, since this area is governed by board interpretation rather than a single statute.
Ownership and clinic licensing
Maryland does not codify a corporate practice of medicine prohibition in the way Texas, New York, or New Jersey do; the doctrine rests on the Medical Practice Act, Attorney General opinions, and case law, and professional entities with management services arrangements are the usual structures. Because the position is not a bright-line statutory rule, published summaries disagree, and ownership structure here is a question for Maryland counsel and the Board of Physicians rather than one a guide should answer with a percentage.
Cold chain into Maryland
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Maryland order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Baltimore | Baltimore City | Largest Maryland market, with academic medical depth. |
| Bethesda | Montgomery | Dense aesthetic and concierge corridor inside the Capital Beltway market. |
| Rockville | Montgomery | Biotech-adjacent market served alongside Bethesda. |
| Columbia | Howard | Central corridor market between Baltimore and Washington. |
| Annapolis | Anne Arundel | Capital market with concierge and wellness practices. |
| Frederick | Frederick | Growing western Maryland market with a biosciences presence. |
- Maryland orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Every vial arrives with the manufacturer’s handling instructions and a Certificate of Analysis, and storage on arrival follows the COA and labeling rather than a general rule.
Wholesale exosome supply by city in Maryland
Each city page covers local receiving conditions, delivery disruptions and business license rules for Maryland practices in that area.
Practice types we supply in Maryland
Maryland licensing and verification
Maryland Board of Physicians
Physicians, physician assistants, and allied health practitioners, with a public license lookup.
Maryland Board of Nursing
RNs and advanced practice certifications, including nurse practitioners.
Maryland Board of Pharmacy
Issues the wholesale distributor permit under Health Occ. title 12, subtitle 6C.
Comptroller of Maryland
Sales and use tax licensing and resale certificates.
Maryland sourcing questions
- Does Maryland have a stem cell law?
- Not a practice law. Section 10-434 of the Economic Development Article creates the Maryland Stem Cell Research Fund, established in 2006 and administered by TEDCO, which is a grant and loan program for state-funded research rather than an authorization to practice, and it is regularly mistaken for a clinical statute. Maryland has no stem cell authorization law, disclosure law, or documentation statute, so exosome products there are governed by federal law, under which no exosome product is FDA-approved for administration to humans.
- Who may a Maryland practice buy prescription drugs or devices from?
- Maryland answers this in statute, which almost no state does. Health Occ. 12-6C-03(f) says a person may not purchase or obtain a prescription drug or prescription device unless it comes from a permitted wholesale distributor, a licensed pharmacist, or an authorized prescriber. The permit duty sits on the distributor, but the sourcing restriction gives the buyer a statutory reason to confirm a supplier’s standing before ordering.
- Does my Maryland clinic need a wholesale distributor permit to buy exosomes?
- No. The wholesale distributor permit under Health Occ. title 12, subtitle 6C is held by the distributor shipping into Maryland, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Can a nurse practitioner run a practice in Maryland without a physician?
- Yes. Maryland repealed the physician attestation requirement through HB 999 of 2015, Chapter 468, effective 1 October 2015, so certified nurse practitioners hold full practice authority and can evaluate and order within NP scope. An applicant for initial certification identifies a certified nurse practitioner or licensed physician as mentor for the first 18 months, and a medical director is still needed where a procedure falls outside NP scope or where a payer requires one.
- Are exosome products FDA approved?
- No exosome product has been approved by the FDA for administration to humans, a position the FDA stated in its 2019 public safety notification on exosome products. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- How long does cold-chain shipping take to Maryland?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Md. Code Ann., Health Occ. 12-6C-03, wholesale distributor permit required; purchasing restriction (accessed 16 October 2026)
- Md. Code Ann., Econ. Dev. 10-434, Maryland Stem Cell Research Fund (accessed 16 October 2026)
- Maryland HB 999 (2015), Certified Nurse Practitioners, Authority to Practice (Ch. 468) (accessed 16 October 2026)
- Maryland Board of Pharmacy (accessed 16 October 2026)
- Maryland Board of Physicians (accessed 16 October 2026)
- Maryland Board of Nursing (accessed 16 October 2026)
- Comptroller of Maryland (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Consensus statementsupports: Supports the page’s core distinction that exosomes are acellular extracellular vesicles, defined and characterized separately from the cells and tissues that stem cell statutes and funds are written around.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: Supports the page’s statement that extracellular vesicle based products remain investigational and that defined manufacturing and documentation is what separates characterized material from uncharacterized material.
- Kou M, Huang L, Yang J, et al. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool?. Cell Death and Disease, 2022. doi:10.1038/s41419-022-05034-x PMID:35787632Narrative reviewsupports: Supports the page’s description of MSC-derived extracellular vesicles, including perinatal MSC-EV preparations, as the source material class whose characterization and provenance a purchasing practice documents.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.